Mihály Józsi Selected Research

Complement Factor H (Factor H)

1/2021	Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
1/2021	FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.
1/2021	Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder.
1/2017	Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.
1/2017	Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.
2/2016	Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.
4/2015	The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
6/2014	Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
7/2013	An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H.
8/2012	Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mihály Józsi Research Topics

Disease

18	Atypical Hemolytic Uremic Syndrome 01/2021 - 01/2006
10	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 01/2021 - 01/2006
7	Infections 01/2021 - 11/2003
6	Kidney Diseases (Kidney Disease) 01/2021 - 09/2007
6	Hemolytic-Uremic Syndrome 01/2019 - 01/2006
6	Macular Degeneration (Age-Related Maculopathy) 01/2018 - 01/2006
5	Inflammation (Inflammations) 01/2022 - 02/2007
5	Hemolysis 01/2017 - 02/2007
3	Thrombotic Thrombocytopenic Purpura 01/2019 - 11/2003
2	Neoplasms (Cancer) 12/2019 - 10/2019
2	Communicable Diseases (Infectious Diseases) 10/2019 - 08/2008
2	Glomerulonephritis 01/2019 - 01/2017
2	Hypersensitivity (Allergy) 03/2018 - 05/2016
2	Eye Diseases (Eye Disease) 02/2012 - 01/2006
2	Acute Kidney Injury (Acute Renal Failure) 01/2012 - 02/2007
1	Amyloidosis 11/2021
1	COVID-19 01/2021
1	Neuromyelitis Optica (Devic's Disease) 01/2021
1	Cytokine Release Syndrome 01/2021
1	Virus Diseases (Viral Diseases) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Thrombotic Microangiopathies 01/2019
1	IGA Glomerulonephritis (IGA Nephropathy) 01/2018
1	Convalescence 01/2017
1	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 04/2016
1	Edema (Dropsy) 12/2015
1	Paraproteinemias (Monoclonal Gammopathy) 04/2012
1	Leptospirosis 03/2012
1	Thrombosis (Thrombus) 09/2009
1	Sepsis (Septicemia) 01/2009
1	Thrombocytopenia (Thrombopenia) 02/2007
1	Immune System Diseases (Immune Disorders) 01/2006

Drug/Important Bio-Agent (IBA)

31	Complement System Proteins (Complement)IBA 01/2021 - 11/2003
18	Complement Factor H (Factor H)IBA 01/2021 - 01/2006
16	AutoantibodiesIBA 01/2021 - 09/2007
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2003
3	LigandsIBA 01/2022 - 02/2012
3	Dichlorodiphenyldichloroethane (DDD)IBA 01/2019 - 04/2010
3	EpitopesIBA 01/2017 - 04/2015
3	factor H-related protein 1IBA 04/2015 - 08/2011
2	thiamine triphosphorate (TTP)IBA 01/2019 - 09/2009
2	Monoclonal AntibodiesIBA 03/2018 - 01/2017
2	Complement Factor B (Factor B)IBA 01/2012 - 04/2010
2	A-factor (Streptomyces)IBA 08/2011 - 02/2007
1	Aquaporins (Water Channels)IBA 01/2021
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2021
1	VaccinesIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	CytokinesIBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Aquaporin 4IBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 12/2019
1	N 30IBA 01/2019
1	Complement C3 (C3 Complement)IBA 01/2019
1	EnzymesIBA 03/2018
1	Contrast MediaIBA 03/2018
1	Peptides (Polypeptides)IBA 01/2017
1	Arginine (L-Arginine)FDA Link 01/2017
1	Tryptophan (L-Tryptophan)FDA Link 01/2017
1	Amino Acids FDA Link 01/2017
1	Drug CarriersIBA 05/2016
1	MicellesIBA 05/2016
1	Liposomes (Liposome)IBA 05/2016
1	eculizumab FDA Link 04/2016
1	Complement Inactivating AgentsIBA 04/2016
1	Leukocyte Elastase (Neutrophil Elastase)IBA 12/2015
1	AntibodiesIBA 06/2014
1	Biological ProductsIBA 01/2014
1	PTX3 proteinIBA 08/2012
1	DNA (Deoxyribonucleic Acid)IBA 02/2012
1	Extracellular Matrix ProteinsIBA 02/2012
1	Immunoglobulin G (IgG)IBA 08/2011
1	Mutant Proteins (Protein, Mutant)IBA 02/2007
1	ADAMTS13 ProteinIBA 11/2003

Therapy/Procedure

2	Therapeutics 01/2021 - 04/2016